Positive data announced from the pivotal part 2 of the SUNFISH trial that evaluated the safety and efficacy of risdiplam in adult and pediatric patients with Type 2 or Type 3 SMA.
Researchers examined the selective vulnerability of the cholinergic system in Alzheimer disease (AD) by exploring the severity of accumulation and neuronal loss in the nucleus basalis of Meynert among AD subtypes.
Higher serum levels of elaidic acid, an objective biomarker for industrial trans fat, are associated with an increased risk for developing all-cause dementia and Alzheimer disease.
Alzheimer disease patients who initiate treatment with antipsychotic medications spend more days hospitalized than those who do not initiate antipsychotics.
The potential for metabolic etiologies for migraine opens a whole new approach to treatment, particularly the opportunity to intervene much earlier in the process.
The incidence of encephalopathy is increased with prescription of higher versus lower doses of baclofen among older patients with chronic kidney disease.
Researchers reported the safety and efficacy of a novel miniaturized neurostimulator, the first-in-human, double-blind pilot study of vagus nerve stimulation, in patients with multidrug refractory rheumatoid arthritis.
